Edit Content

News

Lucent ipl_03

Oculus Partners with LUVO to Offer New IPL and RF Devices

September 28, 2023 Oculus, Inc. has announced a strategic partnership with LUVO to bring new specialty care devices to the U.S. optometry and ophthalmology market. This partnership serves to equip eye care practitioners with the

Izervay

Izervay Approved for the Treatment of Geographic Atrophy

August 8, 2023 TOKYO — Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

xdemvy-lotilaner-ophthalmic

FDA Approves XDEMVY for the Treatment of Demodex Blepharitis

July 25, 2023 IRVINE, Calif.  ­— Tarsus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of demodex blepharitis. XDEMVY, formerly known as TP-03,

A bottle of TobraDex

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

July 18, 2023   NASHVILLE, Tenn. — Harrow Health, Inc. has announced agreements with affiliates of Santen Pharmaceutical Co., Ltd., under which Harrow will acquire certain U.S. and Canadian commercial rights for the following branded

BVI ribbon cutting

BVI Expands IOL Capacity with New Facility in Belgium

July 19, 2023 LIÈGE, Belgium – BVI Medical Inc. has opened a new facility here to increase its intraocular lens (IOL) production capacity. This results in a sizeable increase in BVI’s IOL production capacity, unlocking

RVL Launches ELEVATE Prescription E-commerce Platform

July 6, 2023 BRIDGEWATER, N.J. – RVL Pharmaceuticals has launched ELEVATE, a first-of-its-kind, proprietary prescription e-commerce platform. This platform aligns with RVL’s vision of seamlessly integrating its products into customers’ practices while further enhancing patient

VEVYE eye drops

FDA Approves VEVYE for the Treatment of Dry Eye Disease

June 8, 2023 HEIDELBERG, Germany and CAMBRIDGE, Mass.— Novaliq GmbH, has announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of

Glaukos Announces FDA Acceptance of NDA Submission for iDose TR

May 5, 2023 Aliso Viejo, Calif. – Glaukos Corporation announced it has received the “Day 74” notification from the U.S. Food and Drug Administration acknowledging the previously submitted New Drug Application (NDA) for iDose TR (travoprost intraocular

The ZEISS Cataract Suite with ZEISS CALLISTO® eye for computer assisted cataract surgery

FDA Approves ZEISS CT LUCIA 621P Monofocal IOL

JENA, Germany, and DUBLIN, Calif. – The U.S. Food and Drug Administration (FDA) has approved the CT LUCIA 621P Monofocal IOL from ZEISS Medical Technology. The aspheric, monofocal, single-piece C-loop IOL features the patented ZEISS Optic Asphericity

A surgeon holds the iTrack Advance device.

FDA Clears Way for Launch of iTrack Advance Canaloplasty Device

FREMONT, Calif. — The U.S. Food and Drug Administration has granted 510(k) clearance to Nova Eye Medical Limited’s new canaloplasty device, iTrack Advance. The newest generation canaloplasty device for canal-based glaucoma surgery will be available

FDA Approves SYFOVRE as First and Only Treatment for Geographic Atrophy

FDA Approves SYFOVRE for Geographic Atrophy

WALTHAM, Mass. — The U.S. Food and Drug Administration has approved SYFOVRE (pegcetacoplan injection) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). From global biopharmaceutical company Apellis Pharmaceuticals, Inc., SYFOVRE

FDA Approves Twice-Daily Dosing of Vuity

FDA Approves Twice-Daily Dosing  of Vuity

NORTH CHICAGO, Ill. – AbbVie, the parent company of Allergan, has announced that the FDA has approved a twice-daily dosing option of Vuity (pilocarpine HCl ophthalmic solution) 1.25% in adults with presbyopia. Vuity is the

Scroll to Top